QKL注射通过调节RAGE的表达来改善类似阿尔茨海默病的病理
Jinfang Dou1, Xin'ai Zhang2, Chaoqun Hu1
1Beijing University of Chinese Medicine, Beijing, China.
Experimental gerontology
|April 10, 2024
概括
这项研究表明,QKL治疗通过减少粉样蛋白-β (Aβ) 和其载体RAGE. 改善老鼠阿尔茨海默病 (AD) 症状. 这表明RAGE是AD治疗的关键目标.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默氏症 (AD) 的特征是由于大脑中的粉样β (Aβ) 沉积而导致的神经元损伤.
- 大脑中的过度Aβ与外周血液来源有关,血脑屏障 (BBB) 调节Aβ运输.
- 了解跨BBB的Aβ运输对于探索AD病变的发病过程至关重要.
研究的目的:
- 研究Aβ通过BBB传输在阿尔茨海默病中的作用.
- 在AD的小鼠模型中评估QKL注射的治疗效果.
- 为了确定AD治疗的潜在分子标.
主要方法:
- 使用阿尔茨海默病小鼠模型.
- 进行QKL注射以评估治疗效果.
- 采用了网络药理学,分子对接和分子动力学模拟.
- 测量Aβ水平和Aβ载体RAGE的表达.
主要成果:
- 在AD小鼠中,QKL注射显著改善了认知功能障碍.
- 治疗QKL导致大脑Aβ水平下降.
- QKL的使用降低了Aβ载体RAGE的表达.
- 计算方法支持观察到的效应,并确定RAGE作为一个关键的调解者.
结论:
- QKL证明了阿尔茨海默病的治疗潜力.
- 降低Aβ水平和RAGE表达是QKL有效性的关键机制.
- RAGE代表了基于QKL的阿尔茨海默病治疗的有前途的治疗标.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
08:33Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
Published on: February 28, 2016
13.3K
相关概念视频
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468